Intraperitoneal cisplatin - Mitoxantrone in ovarian cancer patients with minimal residual disease

European Journal of Gynaecological Oncology

Volumn 18, Issue 1, 1997, Pages 71-75

  Topuz, E ^a   Aydiner, A ^a   Saip, P ^a   Bengisu, E ^a   Berkman, S ^a   Disci, R ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Intraperitoneal chemotherapy; Mitoxantrone; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; MITOXANTRONE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; MINIMAL RESIDUAL DISEASE; NAUSEA; NEPHROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; RELAPSE; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; MITOXANTRONE; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PERITONEAL CAVITY; SALVAGE THERAPY;

EID: 0031051924     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Markman M., Reichman B., Hakes T., Curtin J., Jones W., Lewis J. L. et al.: "Intraperitoneal chemotherapy in the management of ovarian cancer". Cancer, 1993, 77, 1565.
2. Hacker N. F., Berek J. S., Pretorius R. G., Zuckerman J., Eisonkop S., Lagasse L. D.: "Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer". Obstet. Gynecol. , 1987, 70, 759.
3. Piver M. S., Lele S. B., Marchetti D. L., Baker T. R., Emrich L. J., Hartman A. B.: "Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma". J. Clin. Oncol., 1988, 6, 1679.
4. Alberts D. S., Woung L., Mason N., Salmon S. E.: "In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration". Semin. Oncol., 1985, 12 (suppl. 4), 38.
5. Alberts D. S., Surwit E. A., Peng Y. M., Mc Closkey T., Rivest R., Graham V. et al.: "Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration". Cancer Res., 1988, 48, 5874.
6. Markman M.: "Intraperitoneal chemotherapy". Semin. Oncol., 1991, 18, 248.
7. Lawton F., Blackledge G , Mould J., Latlef T., Watson R., Chetlyawardana A. D.: "Phase II study of mitoxantrone in epithelial ovarian cancer". Cancer Treat. Rep., 1987, 71, 627.
8. Kaplan E. I , Meier P.: "Nonparametric estimation from incomplete observations". J. Am. Stat. Assoc., 1958, 53, 457.
9. Cox D. R.: "Regression models in life tables". J. R. Stat. Soc. B., 1972, 34, 187
10. Markman M., George M., Hakes T., Reichman B., Hoskins W., Rubin S. et al.: "Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer". J Clin. Oncol., 1990, 8, 146.
11. Reichman B., Markman M., Hakes T., Hoskins W., Rubin S., Jones W. et al.: "Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma". J. Clin. Oncol., 1989, 7, 1327.
12. Weiss G. R., Cortez M. C., Kuhn J. G., Shaffer D.: "Phase I trial of combined intraperitoneal (IP) cisplatin and mitoxantrone for pentoneal cancer". Proc. Am. Soc. Clin. Oncol., 1991, 10, A327.
13. Frasci G., Tortoriello A., Facchini G., Conforti S., Cardone A., Persico G. et al.: "Intraperitoneal (IP) cisplatin-mitoxantrone-interferon-alpha 2b in ovarian cancer patients with minimal residual disease". Gynecol. Oncol., 1993, 50, 60.
14. Lopez J. A., Krikorian J. G., Reich S. D., Smyth R. D., Lee F. H.: "Clinical Pharmacology of intraperitoneal cisplatin". Gynecol. Oncol., 1985, 20, 1.
15. Los G., Mutsaers P. H. A., Vijgh W J. F., Baldew G. S., Graaf P. W., McVie J. G.: "Direct diffusion of cisdiamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison of systemic chemotherapy". Cancer Res., 1989, 49, 3380.
16. Piver M S , Recio F. O., Baker T. R., Driscoll D.: "Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer". Cancer, 1994, 73, 1693.
17. Jong R. S., Willemse P. H. B., Boonstra H., de Vries E. G. E., van der Graaf W. T A., Sleijfer D. T. et al.: "Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer". Eur. J. Cancer., 1995, 31A, 709.
18. Vogl S. E., "Ovarian cancer diagnostic second laparotomy and salvage intra-peritoneal chemotherapy fail again". Eur. J. Cancer, 1995, 31A, 651.
19. Markman M., Reichman B., Hakes T., Jones W., Lewis J. L. Jr., Rubin S. et al.: "Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin". J. Clin. Oncol., 1991, 9, 1801.